latent infections for the lifetime of the host. Human herpesviruses (HHVs) have a distinct tropism for nervous and lymphoid cells, where the body's immune surveillance is limited and the virus can remain undetected. This typically results in cycles of active viral replication (reactivation) and latent periods of infection.
Introduction
Herpesviruses are enveloped, double-stranded DNA viruses that infect both vertebrate and invertebrate animals. Currently, eight different herpesviruses are known to cause disease in humans. All herpesviruses establish chain, block strand elongation. Some of these drugs have severe negative side effects, limited viral specificity, and poor bioavailability and/or toxicity profiles. Additionally, since all of these drugs share the same target, development of resistance is possible. Resistant strains of HHVs have been identified for all currently approved drugs [1] .
Although therapeutic options are available for certain herpesviruses, shortcomings due to specificity, bioavailability, host toxicity, and drug resistance warrant continued research aimed at identifying and developing novel therapies. Proteins that play a role in herpesviral DNA encapsidation have become promising novel chemotherapeutic targets. Two series of related non-nucleoside compounds, N-α-methylbenzyl-N ′ -aryl thiourea analogues, which inhibit either herpes simplex virus (HSV)-1 [1, 2] or VZV [1, 3] DNA encapsidation, have been described. In the presence of thiourea compounds, only B capsids were observed in the nuclei of HSV-or VZV-infected cells. Electron microscopy revealed a lack of DNAfilled capsids in the nucleus for HSV-1-or VZV-infected cells treated with their respective thiourea inhibitor [2, 3] . HSV and VZV mutant viruses resistant to thiourea compounds were found to contain mutations in their putative portal proteins, pUL6 and pORF54, respectively [2, 3] . In a separate study, the HSV-1 portal protein homologue, pUL6, was shown to be the likely target of the HSV-1-specific thiourea compounds [4] . Previously, pUL6 was shown to localize to a single vertex of the viral capsid and is the likely site of entry for viral genomic DNA during the encapsidation process [5, 6] . Additionally, HSV-1 UL6 deletion mutants are defective in both DNA cleavage and packaging, which results in large numbers of B capsids in the nuclei of mutant-infected cells. The effect of inhibiting pUL6 or pORF54 function via thiourea compounds is consistent with the genetic evidence provided by studies with HSV-1 deletion mutants [7, 8] . Thus, a thorough understanding of the interactions between herpesvirus portal proteins and thiourea compounds is of significant interest in the context of developing novel drug treatments for any of the herpesviruses. Herpesviruses and dsDNA bacteriophages both utilize a common process to package their viral genomes into empty procapsids during replication. The specific chain of events following assembly of the procapsid and preceding egress of the viral particle from the nucleus (for herpesviruses [9] ) or cell (for bacteriophage [10] ) is known as DNA encapsidation. The packaging of viral DNA into procapsids is a critical process involving the coordinated interactions of several viral proteins. These include the portal protein, which is located at a single 5-fold vertex of the procapsid, and a complex of several other proteins known as the terminase. The terminase complex binds and cleaves viral DNA into single genome lengths while interacting directly with the portal protein to translocate viral DNA into the procapsid in an ATP-dependent manner.
The eight portal homologues in human herpesviruses range in molecular mass from 68.0 kDa for HHV-8 to 86.8 kDa for VZV ( table 1 a). With the exception of VZV, viruses of the same subfamily tend to have portal proteins of similar mass, most notably the γ-herpesviruses Epstein-Barr virus (EBV; 68.4 kDa) and HHV-8 (68.0 kDa). All of the herpesviruses contain a conserved central core that is in part responsible for the amino acid homology observed between viruses of all subfamilies ( table 1 b; online suppl. fig. S1 describes the highly conserved portal core region found in dsDNA viruses and online suppl. fig.  S2 compares the conserved core of herpesvirus family portal proteins via Raptor X; for all online suppl. material, see www.karger.com/doi/10.1159/000360225). For example, VZV pORF54 amino acid similarity ranges from 42% with human cytomegalovirus (HCMV) to 64% with HSV-1.
It is reasonable to speculate that pORF54 performs a functional role similar to that of pUL6 and other HHV portal proteins as pORF54 shows 44% amino acid identity with its HSV-1 homologue ( table 1 b) [1] . These data, in addition to similar results observed via electron microscopy for inhibitor-treated, infected cells [2, 3] , are predictive of conserved functions for HSV-1 pUL6, VZV pORF54, and the other HHV portals. The location and arrangement of multimeric pUL6 has been resolved within a unique 5-fold vertex of HSV-1 B capsids. More extensive studies of bacteriophage portals have produced X-ray crystal structures of dodecameric portal proteins for bacteriophage SPP1 [11, 12] . Based on previous studies of the HSV-1 and HCMV portal proteins [13, 14] , it is reasonable to assume pORF54 can self-assemble into larger, multimeric structures. Assuming that the VZV portal behaves similarly to other herpesvirus portals, a dodecameric structure would yield a complex of >1.04 MDa -the largest of the HHV portal proteins ( table 1 a) .
Previously, we performed transmission electron microscopy (TEM) on purified pORF54 expressed in a recombinant baculovirus system. It was the first report of the VZV portal protein [15] . However, we were not able to obtain any non-axial orientations of the portal complex. In this study, samples of the previously isolated pORF54 were diluted in 1.0 M arginine buffer at room temperature and gently sonicated with a probe sonicator. TEM revealed a more even distribution of portals, i.e. less 124 aggregation and elimination of portal 'balls', and showed structural features of the VZV portal not observed previously. TEM of purified, diluted, and sonicated VZV pORF54 stained with 1% phosphotungstic acid (PTA) on glowdischarged grids is shown in figure 1 .
Individual portal complexes with non-axial perspectives were observed. Three examples of typical portal proteins, with sizes ∼ 25 nm in diameter, are shown ( fig. 1 ac) . The central channel is visible in two of the three portals (left and center panels), while the last presents a more lateral view (right). The crown, wing and clip faces are indicated. In figure 1 d, a very distinct central channel, presumably the entry point for viral DNA, was observed. The VZV portal is predicted to be larger than any other portal studied to date. This may explain why certain structural features such as the crown/wing and stem are readily visible in the three examples.
In other TEM analysis ( fig. 2 ), samples were stained with 1% PTA but not glow discharged. Particles were observed with a mushroom-like appearance consistent with the predicted multimeric structure of phage portal proteins for which crystallographic data exist ( fig. 2 a) . Figure  2 b shows contrast-enhanced images of non-glow-discharged portals. The central channel can be observed in all three cases. The similarity of these images to those observed for the HCMV portal by Holzenburg et al. [13] is striking. These TEM studies represent the most revealing examples to date of intact VZV portal proteins.
A number of unique non-nucleoside α-herpesvirus inhibitors have been identified. Novel small molecules that target VZV capsid formation [16] and the HSV helicaseprimase [17] [18] [19] are under study. Further investigation of herpesvirus portals and their associated terminase proteins will likely yield new targets for antiviral drug development. The identification of encapsidation-specific antiviral inhibitors for HSV-1, HCMV, and VZV suggests that the encapsidation process is a valid antiviral target for herpesviral chemotherapy [1-3, 20, 21] . It will be interesting to examine portal formation in the presence of inhibitors in order to identify the precise mechanism of action of the thiourea series. Future studies will focus on the effects of inhibitor treatment on the functional and structural characteristics of VZV portal protein. 
